ReviewFrontiers in medicine2021
The Therapeutic Intervention of Sex Steroid Hormones for Sarcopenia.
Review in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Sex-stratified handgrip strength and adipose-derived inflammatory biomarkers in sarcopenia - a systematic review and meta-analysis.BMC geriatrics · 2025Pooled it
- Endocrinological aspects of sarcopenic obesity.Annals of medicine · 2026Review
- Sex-Specific Differences in Patients with Sarcopenia and Peripheral Artery Disease.Muscles (Basel, Switzerland) · 2026Article
- Nanotechnological Strategies to Promote Skeletal Muscle Regeneration in Aging.International journal of molecular sciences · 2026Review
- Joint associations of physical activity and sleep duration with falls: evidence from the China health and retirement longitudinal study.BMC public health · 2026Article
- Interactions between extracellular vesicles and hormones: review.Animal bioscience · 2026Article
- Malnutrition-Sarcopenia Syndrome in older adults: Causes, consequences, and countermeasures.EXCLI journal · 2026Review
- Creatinine, leucine, and tetrahydrocorticosterone emerge as potential biomarkers for the diagnosis of sarcopenic osteoarthritis in middle-aged and elderly individuals: a cross-sectional exploratory study.Frontiers in molecular biosciences · 2026Article
- Metabolomic biomarker differences of sarcopenia in older patients with sepsis.Frontiers in medicine · 2026Article
- Advancing Precision Diagnosis of Sarcopenic Obesity Through Digital Technologies, Wearables and Omics Data.Life (Basel, Switzerland) · 2025Review
- Irisin regulates the phosphorylation of glucocorticoid receptor Ser212 and Ser234 and mediates glucocorticoid-induced muscle atrophy in mice.Communications biology · 2025Article
- Associations of protein-enriched dietary diversity, anti-inflammatory dietary diversity, and low muscle mass among older Chinese adults: a nationwide cross-sectional analysis.BMC geriatrics · 2025Article
- Current perspectives on sarcopenia: diagnosis and therapeutic approaches.The Korean journal of internal medicine · 2025Review
- Sarcopenia in chronic obstructive pulmonary disease: mechanisms, diagnosis, and management strategies.Annals of medicine and surgery (2012) · 2025Review
- Exposure to volatile organic compounds and sarcopenia risk in US adults based on NHANES.Scientific reports · 2025Article
- Androgens as the "old age stick" in skeletal muscle.Cell communication and signaling : CCS · 2025Review
- Exploration of Pathogenesis and Cutting-Edge Treatment Strategies of Sarcopenia: A Narrative Review.Clinical interventions in aging · 2025Review
- Molecular constraints of sarcopenia in the ageing muscle.Frontiers in aging · 2025Review
- Review
- Connecting the dots: sex, depression, and musculoskeletal health.The Journal of clinical investigation · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia, characterized by the excessive loss of skeletal muscle mass, strength, and function, is associated with the overall poor muscle performance status of the elderly, and occurs more frequently in those with chronic diseases. The causes of sarcopenia are multifactorial due to the inherent relationship between muscles and molecular mechanisms, such as mitochondrial function, inflammatory pathways, and circulating hormones. Age-related changes in sex steroid hormone concentrations, including testosterone, estrogen, progesterone, and their precursors and derivatives, are an important aspect of the pathogenesis of sarcopenia. In this review, we provide an understanding of the treatment of sarcopenia through the regulation of sex steroid hormones. The potential benefits and future research emphasis of each sex steroid hormone therapeutic intervention (testosterone, SARMs, estrogen, SERMs, DHEA, and progesterone) for sarcopenia are discussed. Enhanced understanding of the role of sex steroid hormones in the treatment for sarcopenia could lead to the development of hormone therapeutic approaches in combination with specific exercise and nutrition regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.